Position paper on CDK4/6 inhibitors in early breast cancer

Inhibitors of the cyclin-dependent kinases 4/6 (CDK4/6i) have been practice-changing and are now considered the standard of care in combination with endocrine therapy for the first- or second-line treatment in advanced hormone-receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Recently, CDK4/6i have also emerged as an appealing targeted cancer therapy in early breast cancer, however results of large clinical trials are controversial. This position paper summarizes the evidence, and provides guidance for clinical practice.

Automated summary

Inhibitors of CDK4/6 have become the standard of care in advanced hormone-receptor-positive, HER2-negative breast cancer, and are now being evaluated as a targeted therapy for early breast cancer. However, the results of clinical trials in this setting are controversial. This position paper provides a summary of the evidence and guidance for clinical practice.